AML   

Questions discussed in this category



Many patients have had prior chemotherapy exposure with newly diagnosed AML that may not have classic therapy-related cytogenetics.  How do you a...

I have heard <20% MRD. What about proceeding if patient is hypoplastic after chemotherapy?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

Should the goal always be to proceed to a second transplant? 


Papers discussed in this category


Fertil. Steril., 2013 Sep 05

Cell stem cell, 2017-09-07

Blood,

Blood, 2019-01-03

Leukemia, 2019 Oct 18

N. Engl. J. Med.,

Nature medicine, 2015-02

Pediatric blood & cancer, 2014-03

J Clin Oncol, 2020 May 13